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Background: Current histopathological staging procedures in colon carcinomas depend on midline division of the lymph nodes
with one section of haematoxylin & eosin (H&E) staining only. By this method, tumour deposits outside this transection line may be
missed and could lead to understaging of a high-risk group of stage UICC II cases, which recurs in B20% of cases. A new
diagnostic semiautomated system, one-step nucleic acid amplification (OSNA), detects cytokeratin (CK) 19 mRNA in lymph node
metastases and enables the investigation of the whole lymph node. The objective of this study was to assess whether
histopathological pN0 patients can be upstaged to stage UICC III by OSNA.
Methods: Lymph nodes from patients who were classified as lymph node negative after standard histopathology (single (H&E)
slice) were subjected to OSNA. A result revealing a CK19 mRNA copy number 4250, which makes sure to detect mainly
macrometastases and not isolated tumour cells (ITC) or micrometastases only, was regarded as positive for lymph node
metastases based on previous threshold investigations.
Results: In total, 1594 pN0 lymph nodes from 103 colon carcinomas (median number of lymph nodes per patient: 14, range: 1–46)
were analysed with OSNA. Out of 103 pN0 patients, 26 had OSNA-positive lymph nodes, resulting in an upstaging rate of 25.2%.
Among these were 6/37 (16.2%) stage UICC I and 20/66 (30.3%) stage UICC II patients. Overall, 38 lymph nodes were OSNA
positive: 19 patients had one, 3 had two, 3 had three, and 1 patient had four OSNA-positive lymph nodes.
Conclusions: OSNA resulted in an upstaging of over 25% of initially histopathologically lymph node-negative patients. OSNA is a
standardised, observer-independent technique, allowing the analysis of the whole lymph node. Therefore, sampling bias due to
missing investigation of certain lymph node tissue can be avoided, which may lead to a more accurate staging.
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Lymph node metastases are among the most important prognostic
indicators in colon carcinoma patients and are associated with
increased loco-regional recurrence rates as well as worse 5-year
survival (Merkel et al, 2001a; Croner et al, 2009; Kennedy et al,
2011). Adjuvant chemotherapy represents the standard treatment
in lymph node-positive (stage UICC III) colon carcinoma patients.
Adjuvant treatment improves the 8-year overall survival byB10%
in these cases (Sargent et al, 2009). Interestingly, some subgroups
of lymph node-negative tumours (stage UICC II) have a worse
prognosis compared with stage UICC III carcinomas, for example,
patients suffering from pT4 N0 tumours have a lower 5-year
survival compared with those suffering from pT1-2 N1 tumours.
Furthermore, the recurrence rate of stage UICC II colon carcinoma
patients after complete (R0) resection amounts to 20% (Croner
et al, 2009; Kennedy et al, 2011; Salazar et al, 2011). Nevertheless,
adjuvant treatment is not generally recommended for stage UICC
II colon carcinomas (Merkel et al, 2001b). There are ongoing
discussions on whether lymph node-negative patients with high
risk exist and how these patients can be identified for proper
postoperative treatment. Several clinical and molecular classifiers
within the primary tumour have been identified to select these
cases (Rosenberg et al, 2002; Meyer et al, 2009; Sargent et al, 2009;
Gray et al, 2011; Salazar et al, 2011). But none of these molecular
classifiers have made it to clinical routine so far.
A different approach to identify stage I and II patients who may
benefit from adjuvant chemotherapy is a thorough assessment of
lymph nodes, which were determined as metastases-free by routine
haematoxylin & eosin (H&E) analysis. However, step sectioning
and immunohistochemistry are not commonly carried out for
lymph node investigations and most pathologists use only a single
slice of H&E staining. Therefore, small tumour deposits outside the
midline transaction line of the lymph node may be missed during
routine histopathological work-up and result in understaging of
patients (Iddings et al, 2006; Davies et al, 2008).
One-step nucleic acid amplification (OSNA) is a novel
technique to amplify mRNA directly from tissue lysates in an
isothermal manner and has been developed to provide quantitative
measurement of cytokeratin 19 (CK19) mRNA expression. In
contrast to current routine histopathological procedures, it enables
the workup of the whole lymph node in sufficient time under
clinical conditions. Lymph node metastases in breast and colorectal
carcinomas can be correctly identified by this procedure (Croner
et al, 2010; Cserni, 2012; Guller et al, 2012; Yamamoto et al, 2013).
The objective of the present prospective, European multicentre
study was to assess whether histopathological pN0 staged patients
can be upstaged to stage UICC III by OSNA analyses. Patients
recruited for this study were not included in recent single-
institutional investigations demonstrating the accuracy of OSNA
for lymph node staging in colorectal carcinomas (Croner et al,
2010; Guller et al, 2012).
PATIENTS AND METHODS
Patients. The study was carried out after ethical approval was
obtained from the included European study centres from Germany
(Erlangen, Munich), Switzerland (Baden, Basel, Berne, St Gallen)
and Spain (Lleida). Patients with histopathology-proven colon
adenocarcinomaX18 years between 2010 and 2012 were recruited
after obtaining informed consent. Patient characteristics are listed
in Table 1. Patients with synchronous second colon carcinomas,
distant metastases (Mþ ) or neoadjuvant treatment prior to
surgery were excluded from this study. Tumours with a distance of
at least 16 cm proximal to the anal verge measured with a rigid
endoscope were classified as colon carcinomas. Colon resection
was performed either by open complete mesocolic excision or by
laparoscopic techniques, with a standardised regional lymphade-
nectomy (West et al, 2010; Lee et al, 2012). Immediately after
surgery, the entire tumour-bearing specimen was delivered to an
experienced pathologist who harvested the lymph nodes from the
fresh mesocolon, following a standardised study protocol.
Study design. This study was designed to assess the potential
upstaging rate of colon carcinoma patients by OSNA from stage
UICC I/II after standard histopathology (one level of H&E
staining) to stage UICC III (Figure 1). In this prospective study,
the decision whether adjuvant treatment was administered was
based on the histopathology results only, not on the OSNA results.
Lymph node workup. Lymph nodes were harvested as fresh
specimens immediately after surgery. Involved pathologists under-
went a special training for this procedure. Upon preparation of a
lymph node, a 1mm middle slice was immediately cut, and the two
other lymph node pieces designated for OSNA were placed in a
sterile tube and put into liquid nitrogen or on ice (Figure 2).
Initially, the 1mm middle slices of all lymph nodes were
investigated by standard histology (one section of H&E staining)
and the remaining parts of the lymph nodes were stored at  80 1C
until OSNA analysis was performed. Owing to limited amount of
tissue, lymph nodes o3mm in diameter were excluded from
OSNA analysis, but were investigated by histopathology only. If all
lymph nodes were negative by histopathology (pN0), the
remaining frozen parts of the lymph node were investigated by
OSNA at the study centres in Erlangen and Lleida. Olten samples
were analysed in Basel, and Munich samples were shipped to
Erlangen, Basel, and Luebeck for OSNA analysis. If at least one
lymph node was positive by histopathology (macro-metastasis or
micro-metastasis), no OSNA analysis was performed. If at least one
lymph node was positive by OSNA in a patient who was pN0 after
standard H&E analysis, the patient was regarded as upstaged. If all
remaining lymph nodes were negative by OSNA, the patient was
not regarded as upstaged (Figure 1).
Histopathology and CK19 immunohistochemistry. For all
primary tumours, immunohistochemistry was performed for
CK19 receptor (CK19 mouse monoclonal primary antibody) by
the participating centres (Baloch et al, 1999; Uen et al, 2007).
Sections of 1mm size were cut from paraffin blocks mounted on
superfrost glass slides, put in an incubator, and stained
automatically. Tissue sections were then counterstained in the
automated stainer with haematoxylin and treated with a bluing
reagent. Evaluation of each immunohistochemical staining was
performed by light microscopy at a magnification of 10–40-fold.
A positive membranous expression with or without cytoplasmic
staining in X10% of neoplastic cells qualified the case as ‘positive
(þ )’ for CK19. Every single colon carcinoma was stained and
scored for CK19 as well as a fraction of randomly selected lymph
nodes that were histologically detected positive (Figure 3).
One-step nucleic acid amplification. The lymph node tissue
designated for OSNA (maximum weight of 600mg per sample
run) was shock frozen and stored at  80 1C until further use.
OSNA analysis was performed no later than 6 months after
sampling. If the tissue from one lymph node exceeded 600mg, it
was divided into portions weighing o600mg. Each portion was
analysed as a separate OSNA sample. Rapid RNA detection was
achieved by homogenising slices of the dissected lymph node and
directly amplifying CK19 mRNA without prior extraction or
purification of nucleic acids (DNA and/or RNA). A designated
reagent system was used for this method, according to the
instructions for use of the manufacturer (Sysmex, Kobe, Japan). On
the basis of previous investigations, an OSNA result designated as
(þ þ ) has a CK19 mRNA copy number X5000, and that
designated as (þ ), between 250–4999. Less than 250 copies were
considered as a negative result. This cutoff was defined in previous
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Table 1. Patient demographics, tumour characteristics and histopathological criteria,
Patients OSNA negative OSNA positive
Characteristic n % n % n % P
Total 103 100 77 74.8 26 25.2
Gender
Female 49 47.6 35 71.4 14 28.6
Male 54 52.4 42 77.8 12 22.2 0.50
Age
Median (range) 71 (23–92) 71 (23–90) 71 (50–92) 0.8
Surgery
Open 81 78.6 58 71.6 23 28.4
Laparoscopic 22 21.4 19 86.4 3 13.6 0.27
Length of resected colon (cm)
Median (range) 29.5 (8–73) 27 (8–73) 33.5 (15–65) 0.27
Tumour localisation
Coecum 20 19.4 12 60 8 40
Ascending colon 34 33 27 79.4 7 20.6
Right flexure 2 1.9 2 100 0 0
Transverse colon 7 6.8 5 71.4 2 28.6
Left flexure 1 1 1 100 0 0
Descending colon 9 8.7 5 55.6 4 44.4
Sigmoid colon 30 29.1 25 83.3 5 16.7 0.34
Tumour size (cm)
o5 cm 65 63.1 50 76.9 15 23.1 0.65
X5 cm 38 36.9 27 71.1 11 28.9
Median, cm (range) 4 (0.5–16) 4 (0.7–12) 4.5 (0.5–16)
T-category
T1 9 8.7 7 77.8 2 22.2
T2 28 27.2 24 85.7 4 14.3
T3 58 56.3 41 70.7 17 29.3
T4 8 7.8 5 62.5 3 37.5 0.18
Histological grade
Well (G1) 5 4.9 4 80 1 20
Moderate (G2) 80 77.7 57 71.2 23 28.8
Poor (G3) 18 17.5 16 88.9 2 11.1 0.32
Lymphatic invasion
Yes 9 8.7 6 66.7 3 33.3
No 94 91.3 71 75.5 23 24.5 0.69
Vascular invasion
Yes 7 6.8 5 71.4 2 28.6
No 96 93.2 72 75 24 25 1.0
Perineural invasion (Pn)
Yes 11 14.1 7 63.6 4 36.4
No 67 85.9 53 79.1 14 20.9 0.27
Not determined 25
R (resection status)
R0 103 100 77 74.8 26 25.2 NS
R1 0 0 0 0 0 0
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studies to make sure that mainly macrometastases (40.2mm) and
not only micrometastases (p0.2mm) or isolated tumour cells were
scored as metastastic disease (Tsujimoto et al, 2007; Croner et al,
2010; Guller et al, 2012).
Statistical analysis. All statistics have been calculated using SAS
9.2 software (SAS Institute Inc., 2010b). The Cochran-Armitage
test for trend was appropriate for a two-way table where one
variable has two levels and the other variable is ordinal (P, 1955).
The two-level variable represents the response, and the other
variable represents an explanatory variable with ordered levels. The
trend test is based on the regression coefficient for the weighted
linear regression of the binomial proportions on the scores of the
explanatory variable levels. The exact option was used to calculate
P-values (SAS Institute Inc., 2010a). The Exact Fisher Test was
used for calculating P-values for all frequency tables. Arithmetic
means of metric variables were compared by t-test statistics using
the pooled variance for calculating the error term. In all cases, two-
sided P-values were reported. After adjustment for multiple testing
according to Holm–Bonferroni procedure, the critical value for
significance that warrants a global alpha of 0.05 becomes 0.003.
RESULTS
Patient characteristics and tumour histopathology. A total of
103 patients with histopathological pN0 tumours (stage UICC I, II)
were included in this prospective, European, multicentre study.
Median age was 71 (range 23–92) years. Eighty-one patients
(78.6%) underwent open surgery and 22 (21.4%) underwent
laparoscopic procedures. All patients underwent a complete
removal of the tumour-bearing tissue (R0 resection). The median
length of the resected colon was 29.5 cm (range 8–73).
Table 1. ( Continued )
Patients OSNA negative OSNA positive
Characteristic n % n % n % P
LNs from fresh tissue for OSNA
Median, n (range) 14 (1–46) 12 (1–39) 18 (4–46)
o12 LN 43 41.7 37 86.0 6 14
X12 LN 60 58.3 40 66.7 20 33.3 0.04
LNs from remaining formalin-fixed tissue
Median, n (range) 5 (0–28) 5 (0–28) 4 (0–15)
o7 60 58.3 43 71.7 17 28.3
X7 43 41.7 34 79.1 9 20.9 0.49
Abbreviations: LNs¼ lymph nodes; OSNA¼one-step nucleic acid amplification.













At least 1 LN
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Figure 1. Study design for upstaging of histopathology lymph node-
negative colon carcinomas into lymph node-positive tumours by one-
step nucleic acid amplification (OSNA) technology (þ þ ) has a CK19
mRNA copy numberX5000, a (þ ) between 250–4999. Abbreviations:




Figure 2. Lymph node preparation for histopathology and OSNA
work-up. The middle part of the lymph node was analysed by
histopathology (haematoxylin & eosin (H&E) staining of one slice) for
lymph nodes 46mm in greatest diameter. For lymph nodes with
4–6mm the lymph node was bisected and one half underwent OSNA
analysis. If the lymph node was p3mm, it was excluded from OSNA
analysing. In case of negative H&E staining, the lateral parts or the
other half of the lymph nodes were transferred to OSNA analysing.
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Most tumours were localised in the coecum (19.4%), ascending colon
(33%), or sigmoid colon (20.4%). Median tumour size was 4 cm
(range: 0.5–16). Most patients had T3 (56.3%) and T2 (27.2%)
tumours. Most carcinomas (80%) were moderately or well differ-
entiated (G2) and showed neither lymphatic invasion (91.3%) nor
vascular (93.2%) or perineural invasion (85.9%) (Table 1).
As a quality control of CK19 positivity, all primary tumours
were analysed by immunohistochemistry. All included samples
were positive for CK19 protein expression.
Lymph node harvesting. A median of 14 lymph nodes (range
1–46) was harvested from fresh specimens. In patients undergoing
laparoscopic surgery (mean: 11), less number of lymph nodes were
sampled from fresh specimen compared with open procedures
(mean: 17; P¼ 0.007). After formalin fixation of the remaining
tissue, an additional median of 5 lymph nodes (range 0–28) were
identified and embedded for histopathological workup only. The
median total number of harvested lymph nodes (fresh and
formalin fixed) for open and laparoscopic surgery was thus 22
and 16, respectively. In total, 1594 lymph nodes from 103 colon
carcinoma specimens (median number per patient: 14, range:
5–46) were analysed with OSNA. In all but two patients (10 and 11
lymph nodes)X12 lymph nodes were harvested in fresh tissue and
after formalin fixation of the specimens.
OSNA positivity in histopathological pN0 tumours. Of the 103
histologically pN0 patients, 26 were positive with OSNA, resulting
in an upstaging rate of 25.2%. Of these, 6/37 (16.2%) stage I UICC
colon carcinoma patients and 20/66 (30.3%) stage UICC II patients
were upstaged. Nineteen patients had one OSNA-positive lymph
node, three had two, three had three, and one had four OSNA-
positive lymph nodes (Table 2). Patients with T1, T2, and T4
tumours had only one positive lymph node, whereas all multiple
OSNA-positive lymph nodes were found in patients with T3
tumour. Furthermore, 9/10 patients with a (þ þ ) OSNA result
were found in the group of T3 tumour patients (Table 2).
Of the 38 OSNA-positive lymph nodes, 28 had CK19 mRNA
copy number between 250–4999/ml (þ ), indicating a small tumour
load, and 10 lymph nodes had copy numbers X5000, indicating a
higher tumour load (Croner et al, 2010). Correlation between
OSNA upstaged patients and clinicopathological criteria was
identified for gender, age, length of resected specimen, grade,
tumour stage, tumour size and vascular/lymphatic or perineural
invasion with OSNA positivity (Table 1). In patients with o12
lymph nodes, which were mainly found in the group undergoing
laparoscopic procedures, the percentage of OSNA-positive cases
was considerably lower than in patients with X12 lymph nodes
investigated (P¼ 0.04). Of the 38 OSNA-positive lymph nodes, 22
were located p5 cm and 7 were located 45 cm from the primary
tumour. No information regarding the localisation is available in 9
OSNA-positive lymph nodes.













T1 9 2 2 (1) 1þ
1þ þ
T2 28 4 4 (1) 4þ
T3 58 17 10 (1) 8þ
3 (2) 9þ þ
3 (3)
1 (4)
T4 8 3 3 (1) 3þ
Abbreviations: LNs¼ lymph nodes; OSNA¼one-step nucleic acid amplification. OSNA
result designated as (þ þ ) has a CK19 mRNA copy numberX5000, (þ ) between 250–4999.
Figure 3. Haematoxylin & Eosin (H&E) staining (A, B) and CK19 immunohistochemistry (C, D) of the primary tumour (A, C) and lymph node
metastasis (red arrow: B, D) of colon carcinoma.
Molecular staging of lymph node-negative colon carcinomas BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.170 5
DISCUSSION
In the present prospective, European, multicentre study – the largest
so far published trial – OSNA resulted in an upstaging of over 25%
of initially nodal-negative patients after conventional H&E analysis.
OSNA provides a standardised technique allowing the analysis of the
whole lymph node, thereby avoiding sampling bias due to missing
investigation of certain lymph nodes and leading to more accurate
staging. During the current clinical routine, only one slice in the
midline area of the lymph node is investigated by H&E staining.
Tumour deposits outside this area may be missed.
Tumour recurrence in stage UICC II colon carcinomas amounts
to 20% after surgery with complete removal of the carcinoma-
bearing specimen. Based on this unsettling fact, there is an ongoing
debate if stage UICC II patients should receive chemotherapy.
Several studies identified prognostic genes that may select high-risk
patients for adjuvant treatment (Croner et al, 2008; Gray et al,
2011; Kennedy et al, 2011; Salazar et al, 2011; Nitsche et al, 2012;
Maak et al, 2013). But none of these marker panels have made it
into clinical practice so far. During routine histopathology,
following H&E sectioning of lymph nodes, metastatic spread
beneath the sectioned area may be missed and therefore such
patients are understaged as pN0. Hence, methods are urgently
needed that enable the investigation of the whole lymph node in a
timely and feasible manner. OSNA is a novel molecular technology
for CK19 mRNA-based identification of lymph node metastases in
breast cancer and colorectal carcinomas (Tsujimoto et al, 2007;
Croner et al, 2010; Yamamoto et al, 2011, 2013; Guller et al, 2012).
The enormous advantage of this method is that the complete
lymph node can be homogenised and transferred to OSNA without
prior preparation, thus reducing the risk of potential contamina-
tion. The procedure is standardised and has a flat learning curve,
which makes the procedure sufficient for clinical use. Furthermore,
the results are ready within 20min for one lymph node and within
30–40min for 3–4 lymph nodes. Serial sections of the whole node
for histology or immunohistochemistry are time consuming and
can therefore not be performed routinely. Hence OSNA is more
appropriate for clinical routine procedures. We found that the
upstaging rate correlates with the number of lymph nodes analysed
and with tumour stage. Notably, the OSNA upstaging rate in the
present investigation for stage UICC I and II patients was 16.2%
and 30.3%, respectively. The overall upstaging was 25.2%, which is
within the reported recurrence rates for stage I and II colon
carcinoma patients. Therefore, it can be hypothesised that stage
UICC I and II patients who suffer from recurrent disease were
understaged by conventional H&E analysis and were in reality in
stage UICC III. To make sure that we identified not only
micro-metastases or ITCs, which are still under discussion
regarding their prognostic value, we defined a copy number
4250 CK19 mRNA copies as a positive value (Guller et al, 2012).
This threshold was identified in previous feasibility studies where
ITCs were negative for OSNA in over 95% of cases respecting this
cutoff. In histopathological workup, lymph nodes are completely
embedded, but often only a single H&E-stained slide is assessed for
each lymph node. Hence, nonsectioned tumour deposits to the left
and right of this area, deeper in the paraffin block, may well be
missed and staging biases may occur. To prove that OSNA
upstaging of node-negative patients is associated with a higher
recurrence rate, all patients in the present study will be followed for
at least 5 years, with survival analysis after 3 and 5 years. However,
these results are not yet mature. The T3 patient group was not only
the largest group (56.3%) among the pN0 patients in the present
study, but it also seems to have the most important upstaging
potential. This is intuitive, as the T1/T2 group with a more
favourable disease is expected to have a lower rate of lymph node
metastases. Furthermore, it is evident that metastatic tumour cell
spread does not follow a linear lymphatic drain of the carcinoma,
but is more frequent in lymph nodes closely related to the primary
tumour. Whether these lymph nodes are conditioned by tumour-
related cytokines or chemokines and are therefore more recipient
for the seeding of malignant cells remains a matter of debate
(Langheinrich et al, 2012). A statistically significant correlation of
histopathological parameters with OSNA was not reached. One
explanation might be the relatively small study cohort. For
instance, 46 out of 77 patients (59%) in the OSNA-negative cohort
were classified as T3 or T4, whereas this percentage was higher in
the OSNA-positive category (20/26 patients, 77%). Similarly, 7/60
OSNA-negative (12%) vs 4/18 OSNA-positive patients (22%) had
perineural invasion. These findings indicate a relationship of
OSNA with advanced tumours.
We would like to acknowledge the limitations of the present
study. A disadvantage of OSNA is that in homogenised lymph
node tissue-specific lymphadenopathic changes such as an
infiltration by any other tumour or other important changes, for
example, sarcomatoid-like lesions, cannot be detected. However,
these are rare phenomena. Second, fresh or frozen material is
necessary, which renders the lymph node harvesting challenging
and time consuming, because the lymph node preperation in the
mesenterial fat prior to formalin fixation requires experience
(Guller et al, 2012). However, the potential benefit of precise
staging by OSNA outweighs these shortcomings.
In summary, the present prospective, European, multicentre
study – the largest one in the literature – OSNA demonstrated an
upstaging in about one-fourth of colon carcinoma patients
previously diagnosed as pN0 by routine histopathology. These
findings confirm the technical feasibility of lymph node staging of
colon carcinoma patients as recently described (Croner et al, 2010;
Guller et al, 2012; Yamamoto et al, 2013). OSNA appears to be a
more accurate method of staging colon carcinoma patients, and
identifies pN0 individuals who may benefit from adjuvant
treatment. As a next step, a randomised controlled trial is planned,
allocating patients to either OSNA (entire node without H&E) vs
standard H&E pathological analyses to evaluate OSNA as a method
of routine staging in clinical practice.
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